/

Rafael Holdings, Inc.

RFL US

RFL USRafael Holdings, Inc.

United States Composite

1.59

USD

+0.03

(+1.92%)

0.09EPS Dil.

17.09P/E

38.93MMarket Cap

Next Earnings

June 11

Held by Insiders

19.16%

Held by Institutions

11.88%

Short % of Float

0.16%

YTD Yield

-9.31%

3Y Yield

-96.10%

5Y Yield

-88.85%

Capital Structure

FRC

•

in mil. unless spec.

Jul'23

Oct'24

Jan'24

ST Debt

- -

LT Borrowings

- -

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Jul'23

Oct'24

Jan'24

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

-31.00%

- -

Net Income, GAAP

- -

-98.65%

98.40%

Free Cash Flow

-NaN%

-56.63%

57.69%

Total Cash Common Dividend

- -

Total Equity

- -

-2.41%

- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2022

-3

2023

2024

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2022

-5.91

-0.12

-0.28

-0.23

-6.31

2023

0.07

-0.14

-0.06

0.05

-0.08

2024

-0.15

0.26

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2022

- -

2023

- -

2024

- -

Company Description

CEO: Mr. William Conkling
Full Time Employees: 13
Sector: Real Estate
Industry: Real Estate Services
Address: 520 Broad Street Newark NJ United States 07102
CIK: 0001713863
Website: www.rafaelholdings.com
Business: Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Company Description

CEO: Mr. William Conkling
Full Time Employees: 13
Sector: Real Estate
Industry: Real Estate Services
Address: 520 Broad Street Newark NJ United States 07102
CIK: 0001713863
Website: www.rafaelholdings.com
Business: Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.